Patent Assignment
Reel/Frame 075493/0968
Security Interest
Recorded: 2026-04-27
Pages: 25
Assignors
BIOMARIN PHARMACEUTICAL INC.
Executed: 2026-04-27
AMICUS THERAPEUTICS, INC.
Executed: 2026-04-27
Assignee
CITIBANK, N.A., AS COLLATERAL AGENT
388 GREENWICH STREET, 34TH FLOOR, NEW YORK, NEW YORK, 10013
Covered Properties
(347)
Soluble ENPP1 Proteins and Uses Thereof
Variants of C-Type Natriuretic Peptide
Application:
17/073,828 →
High Throughput Screen for Genetic Variants Associated with Short Stature
Application:
19/490,710 →
Dystrophin Exon Skipping Oligonucleotides
Application:
18/192,480 →
Publication:
US US20230348909A1
Dystrophin Exon Skipping Oligonucleotides
Application:
18/654,260 →
Publication:
US US20240368596A1
Treatment of ENPP1 Deficiency and ABCC6 Deficiency in Children
Application:
19/512,793 →
Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
Application:
18/785,340 →
Publication:
US US20240374688A1
Hydrophobic Peptide Salts for Extended Release Compositions
Application:
17/634,034 →
Publication:
US US20220280647A1
C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia in Children
Application:
19/033,994 →
Publication:
US US20250170217A1
CNP Therapy
Application:
18/717,353 →
Publication:
US US20250032576A1
Compositions of Prokaryotic Phenylalanine Ammonia-Lyase Variants and Methods of Using Compositions Thereof
Application:
18/047,824 →
Publication:
US US20240035013A1
Methods for Treating CLN2 Disease in Pediatric Subjects
Application:
17/638,029 →
Publication:
US US20220273775A1
Methods for Treating Lysosomal Storage Diseases
Application:
18/854,132 →
Publication:
US US20250338833A1
Methods for Treating Lysosomal Storage Diseases
Application:
18/529,611 →
Publication:
US US20240158772A1
Adeno-Associated Virus Factor VIII Vectors
Application:
19/025,457 →
Publication:
US US20250332224A1
CNP Variants and Conjugates Thereof
Application:
17/642,150 →
Publication:
US US20230192799A1
Oligomers Having Bicyclic Scaffold Moieties
Application:
18/179,064 →
Publication:
US US20230330128A1
Oligonucleotide
Application:
17/449,290 →
Publication:
US US20220098586A1
Method of Treating Duchenne Muscular Dystrophy
Application:
18/311,789 →
Publication:
US US20230416741A1
Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
Application:
18/916,911 →
Publication:
US US20250295733A1
Treatment of ENPP1 Deficiency and ABCC6 Deficiency
Application:
18/319,821 →
Publication:
US US20240181021A1
Treatment of ENPP1 Deficiency and ABCC6 Deficiency
Application:
18/904,807 →
Publication:
US US20250170223A1
Lyophilized ENPP1 Polypeptide Formulations and Uses Thereof
Application:
18/612,571 →
Publication:
US US20250073319A1
ENPP1 Polypeptides and Methods of Using Same
Application:
19/225,265 →
Publication:
US US20260049294A1
ENPP1 Polypeptides and Methods of Using Same
Application:
18/815,173 →
Publication:
US US20250230423A1
NPP1 Fusion Proteins
Application:
19/183,431 →
Publication:
US US20260022356A1
Method and Compositions for Treatment, Amelioration, and/or Prevention of Diffuse Idiopathic Skeletal Hyperostosis (Dish)
Application:
18/851,844 →
Publication:
US US20260041742A1
Lysosomal Targeting Peptides and Uses Thereof
Application:
17/829,620 →
Publication:
US US20220354934A1
Lysosomal Targeting Peptides and Uses Thereof
Application:
17/815,468 →
Publication:
US US20230241187A1
Compositions of Beta-Hexosaminidase Variants and Uses Thereof
Application:
18/573,298 →
Publication:
US US20240318156A1
Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof
Application:
19/030,525 →
Publication:
US US20250388644A1
Biomarkers For Lysosomal Storage Diseases
Application:
18/698,976 →
Publication:
US US20240424137A1
Recombinant CDKL5 Proteins, Gene Therapy and Production Methods
Application:
17/773,416 →
Publication:
US US20230043046A1
Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
Application:
19/029,413 →
Publication:
US US20250381254A1
Compositions And Methods For Treating Mucopolysaccharidosis IIIA
Application:
18/709,210 →
Publication:
US US20250034533A1
Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System And/Or Lysosomal Storage Disorders
Disulfide Bond Stabilized Polypeptide Compositions And Methods Of Use
Application:
18/808,596 →
Publication:
US US20250242057A1
Dosing Regimens For The Treatment Of Fabry Disease
Application:
18/222,745 →
Publication:
US US20240115708A1
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Pompe Disease
Application:
14/398,210 →
Publication:
US US20150086530A1
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Gene Therapy Constructs and Methods of Use
Application:
18/053,160 →
Publication:
US US20230233711A1
Gene Therapy Constructs for the Treatment of Pompe Disease
Application:
19/147,498 →
Publication:
US US20260216373A1
High Concentration Alpha-Glucosidase Compositions For The Treatment Of Pompe Disease
Application:
19/335,590 →
Publication:
US US20260083829A1
Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates
Application:
18/111,321 →
Publication:
US US20230203465A1
Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates
Application:
19/028,827 →
Publication:
US US20260015600A1
Highly Purified Batches of Pharmaceutical Grade 1-Deoxygalactonojirimycin Compounds
Application:
19/176,778 →
Publication:
US US20250236592A1
Method For Capturing And Purification Of Biologics
Application:
17/640,456 →
Publication:
US US20230220320A1
Method For Selection Of High M6P Recombinant Proteins
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
Application:
17/079,859 →
Publication:
US US20250082621A9
Methods for Treating Infantile-Onset Pompe Disease in Pediatric Patients
Application:
19/134,954 →
Publication:
US US20260207717A1
Methods for Treating Late Onset Pompe Disease in Pediatric Patients
Application:
19/134,958 →
Publication:
US US20260207718A1
Methods for Treating Pompe Disease
Application:
18/863,111 →
Publication:
US US20260041744A1
Methods for Treatment of Fabry Disease
Application:
17/665,969 →
Publication:
US US20220160690A1
Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
Application:
16/642,620 →
Publication:
US US20200222377A1
Methods of Improving the Pharmacokinetics of Migalastat
Application:
18/315,928 →
Publication:
US US20240197706A1
Methods Of Treating Fabry Disease
Application:
17/172,846 →
Publication:
US US20210251972A1
Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
17/909,450 →
Publication:
US US20230136297A1
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
18/473,573 →
Publication:
US US20240207295A1
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
18/473,622 →
Publication:
US US20240293436A1
Methods of Treating Fabry Disease in Patients Having a Mutation in the Gla Gene
Application:
18/479,396 →
Publication:
US US20240277687A1
Methods Of Treating Fabry Disease In Patients Having Renal Impairment
Application:
17/618,277 →
Publication:
US US20220313670A1
Methods of Treating Fabry Disease in Patients Having Renal Impairment
Application:
19/333,835 →
Publication:
US US20260076951A1
Methods of Treating Fabry Disease in Pediatric Patients
Application:
18/578,483 →
Publication:
US US20240293387A1
Methods Of Treating Fabry Patients Having Renal Impairment
Application:
19/184,366 →
Publication:
US US20260097027A1
Neurotensin Variants And Tagged Proteins Comprising Neurotensin Or Sortilin Propeptide
Application:
18/575,512 →
Publication:
US US20240318157A1
Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease
Application:
17/838,741 →
Publication:
US US20230158123A1
Recombinant Human Acid Alpha-Glucosidase
Application:
18/943,360 →
Publication:
US US20250057925A1
Recombinant Human Acid Alpha-Glucosidase and Uses Thereof
Application:
18/276,954 →
Publication:
US US20240197839A1
Treatment Of Fabry Disease In ERT-Naïve And ERT-Experienced Patients
Treatment Of Patients With Classic Fabry Disease
Application:
16/967,824 →
Publication:
US US20210038579A1
Use Of Migalastat For Treating Fabry Disease In Pregnant Patients
Application:
17/838,820 →
Publication:
US US20220387462A1
Use of Migalostat in Reducing the Risk of Cerebrovascular Event in Patients with Fabry Disease
Application:
17/424,979 →
Publication:
US US20220087993A1
Variant IGF2 Constructs
Application:
17/767,803 →
Publication:
US US20240091321A1
Vesicle Targeting Proteins And Uses Of Same
Application:
18/040,866 →
Publication:
US US20240043494A1
Compositions Useful for Treatment of Pompe Disease
Application:
17/998,371 →
Publication:
US US20230173108A1
Compositions Useful for Treatment of Pompe Disease
Application:
17/606,414 →
Publication:
US US20220193261A1
Assay for Detection of Antibodies to Lysosomal Enzymes
Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof
Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof
Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof
Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof
Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof
Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof
Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof
Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof
Manufacture of Active Highly Phosphorylated Human N-Acetylgalactosamine-6-Sulfatase and Uses Thereof
Manufacture of Active Highly Phosphorylated Human N-Acetylgalactosamine-6-Sulfatase and Uses Thereof
Manufacture of Active Highly Phosphorylated Human N-Acetylgalactosamine-6-Sulfatase and Uses Thereof
Proteins with an Attached Short Peptide of Acidic Amino Acids
Cell-Based Assays for Detection of Antibodies or Other Factors That Neutralize Uptake of Lysosomal Enzymes
Variants of C-Type Natriuretic Peptide
Variants of C-Type Natriuretic Peptide
Variants of C-Type Natriuretic Peptide
Patent:
46,707 →
Application:
14/604,262 →
Variants of C-Type Natriuretic Peptide
Patent:
48,267 →
Application:
15/646,822 →
Use of C-Type Natriuretic Peptide Variants to Treat Osteoarthritis
Use of C-Type Natriuretic Peptide Variants to Treat Osteoarthritis
Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia in Children
Method for Producing Alpha Form Crystals of Sapropterin Hydrochloride
Method for Producing Hydrazone Derivatives
Dry Blend Formulation of Tetrahydrobiopterin
Process for Preparing Tetrahydrobiopterin and Analogs of Tetrahydrobiopterin
Methods of Administering Tetrahydrobiopterin, Associated Compositions, and Methods of Measuring
Methods of Administering Tetrahydrobiopterin, Associated Compositions, and Methods of Measuring
Methods of Administering Tetrahydrobiopterin
Patent:
43,797 →
Application:
13/299,499 →
Method of Synthesizing Tetrahydrobiopterin
Stable Tablet Formulation
Compositions of Prokaryotic Phenylalanine Ammonia-Lyase Variants and Methods of Using Compositions Thereof
Compositions of Prokaryotic Phenylalanine Ammonia-Lyase Variants and Methods of Using Compositions Thereof
Compositions of Prokaryotic Phenylalanine Ammonia-Lyase and Methods of Treating Adolescent Subjects
Assays for Detection of Phenylalanine Ammonia-Lyase and Antibodies to Phenylalanine Ammonia-Lyase
Compositions of Prokaryotic Phenylalanine Ammonia-Lyase and Methods of Using Compositions Thereof
Patent:
7,531,341 →
Application:
11/451,999 →
Compositions of Prokaryotic Phenylalanine Ammonia-Lyase and Methods of Using Compositions Thereof
Compositions of Prokaryotic Phenylalanine Ammonia-Lyase and Methods of Treating Cancer Using Compositions Thereof
Compositions of Prokaryotic Phenylalanine Ammonia-Lyase and Methods of Treating Cancer Using Compositions Thereof
Tpp-1 Formulations and Methods for Treating CLN2 Disease
TPP-1 Formulations and Methods for Treating CLN2 Disease
TPP-1 Formulations and Methods for Treating CLN2 Disease
Optimised Coding Sequence and Promoter
Optimised Coding Sequence and Promoter
Optimised Coding Sequence and Promoter
Optimised Coding Sequence and Promoter
Adeno-Associated Virus Factor Viii Vectors
Adeno-Associated Virus Factor Viii Vectors
Adeno-Associated Virus Factor Viii Vectors
Adeno-Associated Virus Factor VIII Vectors
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy
Bispecific Antisense Oligonucleotides for Dystrophin Exon Skipping
Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
Compositions for Treating Pathological Calcification Conditions, Methods, and Host Cells Using The Same
Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
Methods for Treating Pseudoxanthoma Elasticum (PXE)
Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
Compositions for Treating Pathological Calcification Conditions, and Methods Using Same
ENPP1 Polypeptides and Methods of Using Same
NPP1 Fusion Proteins
NPP1 Fusion Proteins
Methods of Treating Tissue Calcification
Methods of Treating Tissue Calcification
Patent:
49,529 →
Application:
17/111,156 →
Compositions and Methods for Treating Pathological Calcification and Ossification
Compositions and Methods for Treating Pathological Calcification and Ossification
Compositions and Methods for Treating Pathological Calcification and Ossification
Compositions and Methods for Treating Pathological Calcification and Ossification
Compositions and Methods for Treating Pathological Calcification and Ossification
Compositions and Methods for Treating Pathological Calcification and Ossification
Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
Compositions and Methods for Modulating Coagulation
Patent:
9,642,896 →
Application:
14/358,166 →
Compositions and Methods for Treating Hemophilia
Compositions and Methods for Treating Platelet Storage Pool Deficiency, Gray Platelet Syndrome and Quebec Platelet Disorder
Compositions and Methods for Treating Nonsteroidal Anti-Inflammatory Drug (Nsaid) Associated Coagulopathy, Thrombocytopenia, Glanzmann's Thrombasthenia, and/or Thrombosis
Compositions and Methods for Stroke Prevention in Pediatric Sickle Cell Anemia Patients
Quantification of Non-Reducing End Glycan Residual Compounds for Determining the Presence, Identity, or Severity of a Disease or Condition
Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof
Lysosomal Targeting Peptides and Uses Thereof
Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof
Detection of Oligosaccharides
Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof
Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof
Glucosylceramide Synthase Inhibitors for the Treatment of Diseases
N-(1-Hydroxy-3-(Pyrrolidinyl)Propan-2-Yl)Pyrrolidine-3-Carboxamide Derivatives as Glucosylceramide Synthase Inhibitors
Nucleic Acids Encoding Targeted Therapeutic Lysosomal Enzyme Fusion Proteins
Histone Deacetylase Inhibitors
Detection of Oligosaccharides
Histone Deacetylase Inhibitors
Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof
Targeted Therapeutic Lysosomal Enzyme Fusion Proteins, Associated Formulations and Uses Thereof
Lysosomal Targeting Peptides and Uses Thereof
Compositions of Prokaryotic Phenylalanine Ammonia-Lyase and Methods of Treating Cancer Using Compositions Thereof
Lysosomal Targeting Peptides and Uses Thereof
Detection of Oligosaccharides
Methods of Determining the Presence and/or Amount of a Biomarker to Determine the Presence, Identity, and/or Severity of a Lysosomal Storage or Neurological Disorder
Methods of Diagnosing a Disease and Methods of Monitoring Treatment of a Disease by Quantifying a Non-Reducing End Glycan Residual Compound and Comparing to a Second Biomarker
Detection of Oligosaccharides
Methods of Diagnosing a Disease and Methods of Monitoring Treatment of a Disease by Quantifying a Non-Reducing End Glycan Residual Compound and Comparing to a Second Biomarker
Quantification of Non-Reducing End Glycan Residual Compounds for Determinging the Presence, Identity, or Severity of a Disease or Condition
Methods of Determining the Presence, Identity, and/or Severity of Mucopolysaccharidosis (Mps) Vi and Iva
Quantification of Non-Reducing End Glycan Residual Compounds for Determining the Presence, Identity, or Severity of a Disease or Condition
Methods of Diagnosing Mucopolysaccharidosis (Mps) I and Methods of Monitoring Treatment of Mps by Quantifying a Non-Reducing End Glycan Residual Compound and Comparing to a Second Biomarker
Quantification of Non-Reducing End Glycan Residual Compounds for Determining the Presence, Identity, or Severity of a Disease or Condition
Glucosylceramide Synthase Inhibitors for the Treatment of Diseases
N-(1-Hydroxy-3-(Pyrrolidinyl)Propan-2-Yl)Pyrrolidine-3-Carboxamide Derivatives as Glucosylceramide Synthase Inhibitors
Quantification of Non-Reducing End Glycan Residual Compounds
Method for the Treatment of Pompe Disease Using 1-Deoxynojirimycin Derivatives
Alpha-Galactosidase a and 1-Deoxygalactonojirimycin Co-Formulation
Alpha-Galactosidase A And 1-Deoxygalactonojirimycin Co-Formulation For The Treatment of Fabry Disease
Alpha-Galactosidase A And 1-Deoxygalactonojirimycin Co-Formulation
Assays for Diagnosing and Evaluating Treatment Options for Fabry Disease
Augmented Acid Alpha-Glucosidase for the Treatment of Pompe Disease
Augmented Acid Alpha-Glucosidase for the Treatment of Pompe Disease
Augmented Acid Alpha-Glucosidase for the Treatment of Pompe Disease
Chemical Crosslinkers
Chemical Crosslinkers
Novel Compounds And Methods For The Treatment Of Alzheimer's Disease And/Or Cerebral Amyloid Angiopathy
Surgical Instrument
Compounds and Methods for Treating or Preventing Disease Conditions Associated with Alpha-1-Antitrypsin
Disulfide Bond Stabilized Polypeptide Compositions and Methods of Use
Disulfide Bond Stabilized Polypeptide Compositions and Methods of Use
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for Treating And/Or Preventing Cerebral Amyloidoses
Drug Package
Patent:
843,850 →
Application:
29/585,388 →
Drug Package
Patent:
877,625 →
Application:
29/605,763 →
Drug Package
Patent:
867,162 →
Application:
29/684,830 →
Drug Package
Patent:
1,082,532 →
Application:
29/801,766 →
Drug Package
Patent:
1,087,752 →
Application:
29/801,769 →
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Gene Therapy Constructs and Methods of Use
Gene Therapy Constructs and Methods of Use
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions For The Treatment Of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates
Highly Potent Acid Alpha-Glucosidase with Enhanced Carbohydrates
Highly Potent Acid Alpha-Glucosidase with Enhanced Carbohydrates
Highly Potent Acid Alpha-Glucosidase with Enhanced Carbohydrates
Highly Purified Batches of Pharmaceutical Grade 1-Deoxygalactonojirimycin Compounds
Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same
Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same
New Method for Preparing Isofagomine and Its Derivatives
Method for Selection of High M6P Recombinant Proteins
Method for Selection of High M6P Recombinant Proteins
Method for the Treatment of Neurological Disorders by Enhancing the Activity of Beta-Glucocerebrosidase
Method for the Treatment of Neurological Disorders by Enhancing the Activity of Beta-Glucocerebrosidase
Method for the Treatment of Neurological Disorders by Enhancing the Activity of Beta-Glucocerebrosidase
Method for the Treatment of Neurological Disorders by Enhancing the Activity of Beta-Glucocerebrosidase
Method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives
Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases
Method for Treating Cerebral Amyloid Angiopathy Using Pharmacological Chaperones to Increase the Activity of Gangliosidases
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
Patent:
48,608 →
Application:
16/222,305 →
Methods for Coupling Targeting Peptides Onto Recombinant Lysosomal Enzymes for Improved Treatments of Lysosomal Storage Diseases
Methods for Coupling Targeting Peptides Onto Recombinant Lysosomal Enzymes for Improved Treatments of Lysosomal Storage Diseases
Methods for Preventing and/or Treating Lysosomal Storage Disorders
Methods for Treating Parkinsons Disease and Parkinsonism
Methods For Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Methods Of Treating Fabry Patients Having Renal Impairment
Methods of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Mouse Model for Pompe Disease and Methods of Use Thereof
Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System
Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System
Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System
Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System
Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System And/Or Lysosomal Storage Disorders
Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
Compounds And Methods For The Treatment Of Alzheimer's Disease And/Or Cerebral Amyloid Angiopathy
Novel Glycohydrolase Inhibitors, Their Preparation and Use Thereof
Patent:
5,844,102 →
Application:
08/301,601 →
Novel Signal Sequences to Improve Protein Expressions and Secretion of Recombinant Enzymes and Other Proteins
Periodic Acid-Schiff Staining with Detection in the Infrared Range
Pharmacological Chaperones for Treating Obesity
Pharmacological Chaperones for Treating Obesity
Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease
Recombinant Human Acid Alpha-Glucosidase
Regimens For Treating And Preventing Lysosomal Disorders And Degenerative Disorders Of The Central Nervous System
Stable Parenteral Dnj Compositions
Stable Parenteral DNJ Compositions
Sugar Derivatives Comprising Sulfur-Containing Moieties and Methods of Making Same and Methods of Using the Same for the Treatment of Mps Iiic
Tartrate Salt of Isofagomine and Methods of Use
Treatment of Cns Disorders Associated with Mutations in Genes Encoding Lysosomal Enzymes
Treatment of Fabry Disease in Ert-NaïVe and Ert-Experienced Patientn
Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease
Use of Migalastat for Treating Fabry Disease in Pregnant Patients
Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
Variant, Recombinant Beta-Glucocerebrosidase Proteins with Increased Stability and Increased Retained Catalytic Activity
Variant, Recombinant Beta-Glucocerebrosidase Proteins With Increased Stability And Increased Retained Catalytic Activity
Variant, Recombinant Beta-Glucocerebrosidase Proteins With Increased Stability And Increased Retained Catalytic Activity
Variant, Recombinant Beta-Glucocerebrosidase Proteins With Increased Stability And Increased Retained Catalytic Activity
Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
Compounds and Methods for the Treatment of Alzheimer's Disease and/or Cerebral Amyloid Angiopathy
Hydroxy Piperidine Derivatives to Treat Gaucher Disease
New Method for Preparing Isofagomine and Its Derivatives
Tartrate Salt of Isofagomine and Methods of Use
Related Assignments
(23)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 13, 2022
From: VAN DEUTEKOM, JUDITH CHRISTINA THEODORA; DE VISSER, PETER CHRISTIAN
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 058651/0342 →
Assignment of Assignor's Interest
Mar 1, 2022
From: ANG, JAKE; BATTU, SUNIL KUMAR; LABER, JOSHUA
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 059132/0792 →
Assignment of Assignor's Interest
Mar 17, 2022
From: ESTRADA, KAROL; LEBOWITZ, JONATHAN; CHOU, JOYCE
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 059293/0581 →
Assignment of Assignor's Interest
Sep 20, 2022
From: WENDT, DANIEL J.; BERGUIG, GEOFFREY; ESTRADA, KAROL; LEBOWITZ, JONATHAN
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 061150/0843 →
Assignment of Assignor's Interest
Oct 19, 2022
From: OKHAMAFE, AUGUSTUS O.; BELL, SEAN M.; ZECHERLE, G. NICK; ANTONSEN, KRIS
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 061472/0335 →
Assignment of Assignor's Interest
Apr 28, 2023
From: JACOBY, DAVID; HENSHAW, JOSHUA
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 063483/0012 →
Assignment of Assignor's Interest
Jul 11, 2023
From: FROELICH, STEVEN MICHAEL; WOLOSZYNEK, JOSH; MAGAT, JENNA MARIE; VAN DEUTEKOM, JUDITH CHRISTINA THEODORA
To: BIOMARIN PHARMACEUTCAL INC.
Reel/Frame 064214/0962 →
Assignment of Assignor's Interest
Sep 28, 2023
From: VAN DEUTEKOM, JUDITH CHRISTING THEODORA; DE VISSER, PETER CHRISTIAN
To: BIOMARIN TECHNOLOGIES B.V.
Reel/Frame 065082/0439 →
Assignment of Assignor's Interest
Oct 24, 2023
From: HUERTAS, PEDRO; WENKERT, DEBORAH
To: INOZYME PHARMA, INC.
Reel/Frame 065326/0988 →
Assignment of Assignor's Interest
Apr 4, 2024
From: ANG, JOOCHUAN; CHOU, TIAN WEI
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 067008/0591 →
Assignment of Assignor's Interest
Apr 4, 2024
From: BRADDOCK, DEMETRIOS; STABACH, PAUL
To: YALE UNIVERSITY
Reel/Frame 067009/0554 →
Assignment of Assignor's Interest
Apr 4, 2024
From: CHENG, ZHILIANG; JUNGLES, STEVEN
To: INOZYME PHARMA, INC.
Reel/Frame 067009/0515 →
Assignment of Assignor's Interest
May 9, 2024
From: JUNGLES, STEVEN
To: INOZYME PHARMA, INC.
Reel/Frame 067366/0923 →
Assignment of Assignor's Interest
Jul 2, 2024
From: HARTL, THOMAS AARON; WOLOSZYNEK, JOSH CHRISTOPHER; FROELICH, STEVEN MICHAEL; KOEHLER, CHARLES FRANCIS, V
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 068118/0370 →
Assignment of Assignor's Interest
Jul 26, 2024
From: BULLENS, SHERRY; BUNTING, STUART; CHOU, TIANWEI; OKHAMAFE, AUGUSTUS O.
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 068093/0503 →
Assignment of Assignor's Interest
Sep 9, 2024
From: O'NEILL, CHARLES A.; BHAGWAT, SHRIPAD S.; NEIL, DAVID RILEY; JACOBY, DAVID REID
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 068524/0272 →
Nunc Pro Tunc Assignment
Sep 10, 2024
From: MOSS, JASON ALAN
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 068541/0112 →
Assignment of Assignor's Interest
Oct 24, 2024
From: HUERTAS, PEDRO; WENKERT, DEBORAH
To: INOZYME PHARMA, INC.
Reel/Frame 069008/0022 →
Assignment of Assignor's Interest
Nov 14, 2024
From: SLEAT, DAVID; LOBEL, PETER
To: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Reel/Frame 069258/0921 →
Assignment of Assignor's Interest
Nov 19, 2024
From: JEHA, GEORGES; BAUER, CHRISTOPHER; COVARRUBIAS, SERGIO; SHANGHAVI, DEVANSHI
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 069324/0411 →
Assignment of Assignor's Interest
Jan 22, 2025
From: DAY, JONATHAN; FISHELEVA, ELENA
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 069967/0593 →
Assignment of Assignor's Interest
Nov 25, 2025
From: INOZYME PHARMA, INC.
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 073707/0488 →
Assignment of Assignor's Interest
Feb 24, 2026
From: COVARRUBIAS, SERGIO; SHANGHAVI, DEVANSHI
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 073874/0816 →